Vision correction

Search documents
Why Making Prescription Meta Ray-Ban Display Glasses Gets Tricky
CNET· 2025-10-01 22:34
one is on my end which is my my own vision. I know there's a prescription limit right now. I'm a minus eight.I was bummed. I've been asking I've been asking Alex about it that you're head of wearables and um what what do you think possibilities are for that. I know there's chance of doing more.I think the goal for these is obviously to get as many people to wear them as possible. Yeah, we have exactly right. We have our interests are super aligned.We want these to be something that everyone can wear today. ...
Ocumetics Announces Completion of First Tranche of Unit Private Placement
Thenewswire· 2025-07-17 13:00
Core Viewpoint - Ocumetics Technology Corp. has successfully completed the first tranche of a private placement, raising a total of $1,124,362 through the issuance of 3,212,462 units at a price of $0.35 per unit [1][2]. Group 1: Private Placement Details - The units issued consist of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of an additional common share at an exercise price of $0.50 for 24 months [2]. - The total offering aims to raise up to $2,100,000 by issuing up to 6,000,000 units at the same price, with the remaining tranches to be closed subsequently [5]. - The net proceeds from the offering are intended for ongoing research and development, although actual allocation may vary based on future operations [5]. Group 2: Agent and Related Transactions - Ocumetics paid $68,610 to Numus Capital Corp. for their services as an agent and issued warrants allowing Numus Capital to purchase up to 196,029 common shares at $0.50 per share for 24 months [3]. - The private placement involved a related party transaction, as a director of the Corporation participated, and the transaction was approved unanimously by the board [6]. Group 3: Company Overview - Ocumetics Technology Corp. is focused on developing advanced vision correction solutions, including innovative intraocular lenses aimed at enhancing the quality of life for patients [7][8]. - The company is currently in the preclinical study stage of a technology designed to potentially eliminate the need for corrective lenses by allowing the eye's natural muscle activity to shift focus [9].